Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 8/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3685568 | 0.90 | AOC3 (0.40) | AOC3HTR2AHRH1 | |
| SCHEMBL6491244 | 0.88 | AOC3 (0.47) | AOC3HTR2AHRH1SIGMAR1ALDH1A1 | |
| SCHEMBL6490032 | 0.81 | AOC3 (0.35) | AOC3HTR2AHRH1SIGMAR1 | |
| SCHEMBL9717165 | 0.81 | AOC3 (0.45) | AOC3SIGMAR1ALDH1A1 | |
| SCHEMBL8773789 | 0.80 | SIGMAR1 (0.39) | AOC3HTR2AHRH1SIGMAR1ALDH1A1 | |
| SCHEMBL87643 | 0.80 | SIGMAR1 (0.46) | AOC3HTR2AHRH1SIGMAR1ALDH1A1 | |
| SCHEMBL4946334 | 0.79 | AOC3 (0.50) | AOC3HTR2AHRH1SIGMAR1ALDH1A1 | |
| SCHEMBL13005300 | 0.78 | HTR2A (0.46) | AOC3HTR2AHRH1SIGMAR1ALDH1A1 | |
| SCHEMBL449304 | 0.78 | ESR1 (0.46) | AOC3MEN1HTTKMT2A | |
| SCHEMBL6488668 | 0.77 | AOC3 (0.41) | AOC3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020035027-A1 | LINKER, ANTIBODY-DRUG CONJUGATE INCLUDING SAME, AND USE THEREOF | 中国人民解放军军事科学院军事医学研究院 | 2020-02-20 | — | — | WO | disclosed |